Abstract:Emerging evidence suggests that GSK3β, a redox-sensitive transducer downstream of insulin signaling, acts as a convergent point for myriad pathways implicated in kidney injury, repair, and regeneration. However, its role in diabetic kidney disease remains controversial. In cultured glomerular podocytes, exposure to a milieu of type 2 diabetes elicited prominent signs of podocyte injury and degeneration, marked by loss of homeostatic marker proteins like synaptopodin, actin cytoskeleton disruption, oxidative stress and apoptosis, and stress-induced premature senescence, as shown by increased staining for senescence-associated β-galactosidase activity, amplified formation of γH2AX foci, and elevated expression of mediators of senescence signaling, like p21 and p16INK4A. These degenerative changes coincided with GSK3β hyperactivity, as evidenced by GSK3β overexpression and reduced inhibitory phosphorylation of GSK3β, and were averted by tideglusib, a highly-selective small molecule inhibitor of GSK3β. In agreement, post-hoc analysis of a publicly-available glomerular transcriptomics dataset from patients with type 2 diabetic nephropathy revealed that the curated diabetic nephropathy-related gene set was enriched in high GSK3β expression group. Mechanistically, GSK3β-modulated nuclear factor Nrf2 signaling is involved in diabetic podocytopathy, because GSK3β knockdown reinforced Nrf2 antioxidant response and suppressed oxidative stress, resulting in an improvement in podocyte injury and senescence. Conversely, ectopic expression of the constitutively active mutant of GSK3β impaired Nrf2 antioxidant response and augmented oxidative stress, culminating in an exacerbated diabetic podocyte injury and senescence. Moreover, IRS-1 was found to be a cognate substrate of GSK3β for phosphorylation at IRS-1S332, which negatively regulates IRS-1 activity. GSK3β hyperactivity promoted IRS-1 phosphorylation, denoting a desensitized insulin signaling. Consistently, in vivo in db/db mice with diabetic nephropathy, GSK3β was hyperactive in glomerular podocytes, associated with IRS-1 hyperphosphorylation, impaired Nrf2 response and premature senescence. Our finding suggests that GSK3β is likely a novel therapeutic target for treating type 2 diabetic glomerular injury.

Investigation for GSK3β Expression in Diabetic Osteoporosis and Negative Osteogenic Effects of GSK3β on Bone Marrow Mesenchymal Stem Cells under a High Glucose Microenvironment.

Hyperglycemia Induces Endoplasmic Reticulum Stress-Dependent CHOP Expression in Osteoblasts

High Glucose Impaired Estrogen Receptor Alpha Signaling Via Β-Catenin in Osteoblastic MC3T3-E1

miR-124-3p promotes BMSC osteogenesis via suppressing the GSK-3β/β-catenin signaling pathway in diabetic osteoporosis rats

Osteoblast-intrinsic defect in glucose metabolism impairs bone formation in type II diabetic male mice

Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro

Hyperglycemia impairs osteoblast cell migration and chemotaxis due to a decrease in mitochondrial biogenesis

MiR-378 Overexpression Attenuates High Glucose-Suppressed Osteogenic Differentiation Through Targeting CASP3 and Activating PI3K/Akt Signaling Pathway.

The Redox-Sensitive GSK3β is a Key Regulator of Glomerular Podocyte Injury in Type 2 Diabetic Kidney Disease

High-glucose-induced Mir-214-3p Inhibits BMSCs Osteogenic Differentiation in Type 1 Diabetes Mellitus

The Inhibition of PINK1/Drp1-mediated Mitophagy by Hyperglycemia Leads to Impaired Osteoblastogenesis in Diabetes

Bradykinin Receptors and EphB2/EphrinB2 Pathway in Response to High Glucose-Induced Osteoblast Dysfunction and Hyperglycemia-Induced Bone Deterioration in Mice

High glucose-induced inhibition of osteoblast like MC3T3-E1 differentiation promotes mitochondrial perturbations

The Impact of Curcumin on Bone Osteogenic Promotion of MC3T3 Cells under High Glucose Conditions and Enhanced Bone Formation in Diabetic Mice

Transcriptomic analysis provides a new insight: Oleuropein reverses high glucose-induced osteogenic inhibition in bone marrow mesenchymal stem cells via Wnt10b activation

Osteogenesis of bone marrow mesenchymal stem cell in hyperglycemia

Genetic activation of glycolysis in osteoblasts preserves bone mass in type I diabetes

Advanced glycation end products mediate biomineralization disorder in diabetic bone disease

VK<sub>2</sub> Promotes Osteogenic Differentiation of BMSCs against High Glucose Exposure <i>via</i> Modulation of Intracellular Oxidative Stress

Investigating the effects and mechanisms of cyclomorusin on osteoclasts in a high glucose environment

High glucose inhibits osteogenic differentiation of bone marrow mesenchymal stem cells via regulating miR-493-5p/ZEB2 signalling